Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Sebastien Lorenzo"'
1
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
Autor: Ying Fei Li, Francois Pierre Combes, Matthias Hoch, Sebastien Lorenzo, Sherwin K. B. Sy, Yu-Yun Ho
Publikováno v: Clinical Pharmacokinetics. 61:1393-1403
Asciminib, a first-in-class, highly potent and specific ABL/BCR-ABL1 inhibitor, has shown superior efficacy compared to bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, treated with two or more ty
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bed89727c5912c6920e1ecba3fee5f
https://doi.org/10.1007/s40262-022-01148-9
Zobrazit plný text záznamu
4
Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection
Autor: Angela Sinn, Lars Blumenstein, Sebastien Lorenzo, Monika Gajewska, Martin Mueller-Zsigmondy, Tycho Heimbach, Maria Velinova, Alexandros Kourentas
Publikováno v: The AAPS Journal. 22
A physiologically based pharmacokinetic (PBPK) human model for alpelisib, an oral α-specific class I phosphatidylinositol-3-kinase (PI3K) inhibitor, was established to simulate oral absorption and plasma pharmacokinetics of healthy subjects to allow
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::013d4d8ad6f5b8a300187c5718423181
https://doi.org/10.1208/s12248-020-00511-7
Zobrazit plný text záznamu
5
A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
Autor: Katharine Hazell, Sebastien Lorenzo, Denes Csonka, Zhanna Kobalava, Vincent Duval, Lucia Trandafir, Edward Waldron
Publikováno v: Journal of Clinical Pharmacology
The pharmacokinetics (PK) and safety of single‐dose buparlisib (30 mg) were assessed in subjects with mild to severe hepatic impairment (n = 6 each) relative to healthy controls (n = 13). Blood samples were collected until 336 hours postdose and ev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3710935f134cfe73181bb32677b2f59
https://doi.org/10.1002/jcph.590
Zobrazit plný text záznamu
6
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin
Autor: Catherine Dutreix, Sebastien Lorenzo, Yanfeng Wang
Publikováno v: European Journal of Clinical Pharmacology
Purpose Midostaurin, a multitargeted tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. This midostaurin drug–drug interaction study assessed the dynamic response and clinical usefulness of urinary 6β-hydroxycortisol to cortisol ratio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d48096d7a398eed98ba629bbac87a9
https://doi.org/10.1007/s00228-014-1675-0
Zobrazit plný text záznamu
7
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
Autor: Sebastien Lorenzo, Joel Morganroth, Alice Huntsman-Labed, Yanfeng Wang, Catherine Dutreix, Robert Harrell, Adam del Corral
Publikováno v: Cancer Chemotherapy and Pharmacology
Purpose Midostaurin (PKC412) is a multitargeted tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 receptor (FLT3), c-KIT, and other receptors. Midostaurin is active in patients with acute myeloid leukemia and systemic mastocytosis. Although no
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21880389f829dd8bebafc1b7e0d012ff
https://pubmed.ncbi.nlm.nih.gov/22294470
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje